Regeneron Reports Two-Year (PULSAR) Trial Results of Eylea HD (aflibercept) for Wet Age-Related Macular Degeneration
Shots:
- The first presentation of positive 2yr. (96wks.) results from the (PULSAR) trial evaluating Eylea HD (8mg) with 12 & 16wk. dosing regimens vs 8wk. dosing regimen for Eylea. The results were presented with the 60wk. results at the 23rd EURETINA Congress
- The trial met its 1EPs i.e., patients achieved clinically equivalent vision gains to Eylea at 48wks. & demonstrated sustained visual and anatomic improvements through 2yrs., 88% & 78% were on a ≥12 & ≥16wk. dosing interval at the end of 2yrs. with 71% meeting the extension criteria for ≥16wk. dosing intervals & 53% eligible for ≥20 dosing week intervals
- The safety was consistent with the known safety profile of Eylea, rate of intraocular inflammation (1.3% vs 2.1)
Ref: Regeneron | Image: Regeneron
Related Post:- Biocon Biologics’ Yesafili (biosimilar, aflibercept) Receives EC’s Approval for Ophthalmic Conditions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.